Strategic collaborations Eutropics has active and growing research partnerships with MD Anderson Cancer Center, USC Keck School of Medicine, Massachusetts General Brigham, and the National University of Singapore, signaling a ready-made pathway for co-development trials and potential tiered diagnostic integrations with large academic and clinical networks.

CLIA validated platform PRIMAB-Dx is being validated within a CLIA framework with a RUO-to-CLIA revenue model, presenting a near-term sellable diagnostic solution for pharma partners running BH3 mimetic and apoptosis-targeted trials, reducing barriers to adoption for oncology sponsors.

Multiple myeloma pipeline Recent collaborations in multiple myeloma with NUS indicate expansion opportunities into hematologic malignancies beyond AML, suggesting cross-indication sales potential and partnerships with clinics active in plasma cell disorders.

Non-dilutive funding traction Historical non-dilutive grants and SBIR funding, totaling over 20 million, demonstrate validated interest and credibility; this can support joint grant-funded studies or co-development deals with OEMs and pharma seeking grant-backed evidence generation.

Revenue-ready platform Current revenue range and scalable biomarker platform position Eutropics as a potential complementary diagnostic add-on for biotech partners developing BH3 mimetics and apoptosis-targeted therapies, enabling faster drug-to-diagnosis alignment and portfolio expansion.